이 페이지는 자동 번역되었으며 번역의 정확성을 보장하지 않습니다. 참조하십시오 영문판 원본 텍스트의 경우.

THE EVALUATION OF THE SAFETY AND PERFORMANCE OF AN INJECTABLE HYALURONIC ACID FILLER

2026년 8월 9일 업데이트: Hallura Ltd.

PROSPECTIVE, INTERVENTIONAL, NON-RANDOMIZED, OPEN LABEL, BLINDED STUDY FOR THE EVALUATION OF THE SAFETY AND PERFORMANCE OF AN INJECTABLE HYALURONIC ACID FILLER

Evaluation of the safety and performance of the investigational device in its three concentrations for cheek and lips augmentation and correction of the nasolabial folds, assuming that the performance of the product will be demonstrated based on the responder rates observed compared to baseline.

연구 개요

연구 유형

중재적

등록 (추정된)

98

단계

  • 해당 없음

연락처 및 위치

이 섹션에서는 연구를 수행하는 사람들의 연락처 정보와 이 연구가 수행되는 장소에 대한 정보를 제공합니다.

연구 연락처

연구 연락처 백업

연구 장소

      • Tel Aviv, 이스라엘
        • 모병
        • Ichilov Medical Center
        • 연락하다:
      • Tel Aviv, 이스라엘, 2069202
        • 완전한
        • Hallura Ltd

참여기준

연구원은 적격성 기준이라는 특정 설명에 맞는 사람을 찾습니다. 이러한 기준의 몇 가지 예는 개인의 일반적인 건강 상태 또는 이전 치료입니다.

자격 기준

공부할 수 있는 나이

  • 성인
  • 고령자

건강한 자원 봉사자를 받아들입니다

예

설명

Inclusion Criteria:

  1. Healthy Subject;
  2. Male or female, over the age of 18;
  3. Female patients of childbearing potential must declare in the ICF to be non-pregnant at visit 1a prior to initial injection and should use a contraceptive regimen recognized as effective since at least 12 weeks before the beginning of the study, and during the entire duration of the study.
  4. Subject seeking an aesthetic procedure on the face who can be classified into one of the following groups:

    1. Group1: Lip volume deficit with ROSSI score between 1.5 and 3 on at least the upper lip, or on both the upper and the lower lips with up to 1-point difference in ROSSI score between upper and lower lips;
    2. Group 2: Moderate to severe nasolabial folds (NLFs) with WSRS scale score 3 or 4 for each side of the face;
    3. Group 3: Mild to significant volume deficit at the cheeks level with MFVDS score 3 to 4 at each side, with up to 1-point difference in MFVDS scale score between the two sides.

    Blinded Live-Evaluator (BLE) and Injector (ILE) must independently agree that the criteria is met on the area to be treated, however concordance of the scores is not required.

  5. Subject willing to abstain from any aesthetic treatment on the treated area other than the treatments planned in the protocol during the study period.
  6. Subject informed and having signed and dated the EC approved informed consent form (ICF).
  7. Subjects agree that his/her imaging will be published without partial covering of the photo, meaning without Anonymization for R&D, business development, Marketing of Hallura and Publications and for evaluating the 3D imaging by cherry imaging for internal R&D use.

Exclusion Criteria:

In terms of population

  1. Subject with abnormal vision assessment at Baseline: either Snellen acuity test worse than 20/40 (with corrections, if applicable) or abnormal confrontational visual field test or abnormal ocular motility test.
  2. Subject who is pregnant or nursing or planning to become pregnant during the study.
  3. Subject with a tattoo, a scar, moles, too many hairs or anything on the studied zones which might interfere with the evaluation.
  4. Subject who had been deprived of their freedom by administrative or legal decision or who is under guardianship, such as social or sanitary establishment.
  5. Subject suspected to be non-compliant according to the investigator's judgment.
  6. Participation in another clinical trial concurrent with this study.

    In terms of associated pathology and concomitant treatment

  7. Subject with a condition or receiving a medication which, in the investigator's judgment, puts the subject under risk.
  8. Subject suffering from a severe or progressive disease or any other pathology that may interfere with the evaluation of the study results.
  9. Subject with mid-face volume deficit due to congenital defect, trauma, abnormalities in adipose tissue related to immune-mediated diseases such as generalized lipodystrophy (e.g., juvenile dermatomyositis), partial lipodystrophy (e.g., Barraquer-Simons syndrome), inherited disease, or HIV-related disease, and/or severe malocclusion or dentofacial or maxillofacial deformities.
  10. Subject with known history of or suffering from autoimmune disease and/or immune deficiency.
  11. Subject suffering from inflammatory and/or infectious cutaneous disorders in or near the studied zones (herpes, acne, mycosis, papilloma, rosacea, blotches or other pathology on the studied zones, at the investigator appreciation). Subject with recurrent herpes is not eligible even if asymptomatic at time of inclusion.
  12. Subject who has a known history of multiple allergies, allergic/anaphylactic reactions including allergy to lidocaine or anaesthetics of the amide type, to hyaluronic acid products, or to Gram-positive bacterial proteins.
  13. Subject with a past history of streptococcal disease, such as acute rheumatic fever or recurrent sore throats.
  14. Subject with a history of precancerous lesions/skin malignancies.
  15. Subject predisposed to keloids or hypertrophic scarring.
  16. Subject with known history of hyper- or hypo-pigmentation in face.
  17. Subject prone to develop inflammatory skin conditions or having tendency to bleeding disorders.
  18. Subject having received high dose of Lidocaine (more than 200mg) and/or high dose of anaesthetics structurally related to amide-type during the week before the injection session.
  19. Have received (or is planning to receive) anti-coagulation, anti-platelet, or thrombolytic medications (e.g., warfarin), anti-inflammatory drugs (oral/injectable corticosteroids or NSAIDs, e.g., aspirin, ibuprofen), or other substances known to increase coagulation time (vitamins or herbal supplements, e.g., Vitamin E, garlic, gingko), fish oil or vitamin C from 10 days pre- to 3 days post injection [Study device injections may be delayed as necessary to accommodate this 10-day washout period.]
  20. For group 1, abnormal rating in lip movement / lip function / lip sensation.
  21. Subject undergoing one of the following systemic or topical (on the test area) treatments:
  22. anti-histamines during the 2 weeks prior to study start;
  23. immunosuppressors and/or corticoids during the 4 weeks prior to study start;
  24. retinoids during the 6 months prior to study start.
  25. Subjects suffering from untreated epilepsy;

    In terms of lifestyle

  26. Subject having received injection with a temporary bioresorbable facial dermal filler (e.g., hyaluronic acid, collagen, autologous fat, etc.) within the past 12 months prior to study start.
  27. Botulinum toxin injections, mesotherapy, or resurfacing (laser, photomodulation, intense pulsed light, radio frequency, dermabrasion, chemical peel, or other ablative or non-ablative procedures) within 6 months prior to entry in the study.
  28. Subjects having received at any time permanent facial implants (e.g. polyacrylamide, PMMA, silicone) anywhere in the face or neck.
  29. Had undergone semi-permanent dermal filler treatment (e.g., calcium hydroxylapatite, poly-L-lactic acid, etc.) in the face within 24 months before enrolment.
  30. Subject having received at any time a treatment with tensor threads or gold strands on the face.
  31. Intensive exposure to sunlight or UV-rays within the previous month and/or foreseen during the study;
  32. Subject with an excessive consumption of alcohol (more than 2 glasses of wine per day) and/or tobacco (more than 10 cigarettes per day).

공부 계획

이 섹션에서는 연구 설계 방법과 연구가 측정하는 내용을 포함하여 연구 계획에 대한 세부 정보를 제공합니다.

연구는 어떻게 설계됩니까?

디자인 세부사항

  • 주 목적: 치료
  • 할당: 무작위화되지 않음
  • 중재 모델: 병렬 할당
  • 마스킹: 없음(오픈 라벨)

무기와 개입

참가자 그룹 / 팔
개입 / 치료
실험적: Group 1 - Lips
HLR-1, maximum of 3ml per upper and lower lip area, (1.5ml max at the touch-up treat

Initial injection of HLR-1 and a touch-up treatment can occur 30 ± 7 days after the initial treatment if the Injector and Subject determine that additional HLR Dermal Filler would improve the aesthetic outcome.

The Maximum allowable dose for the touch up treatments is half of initial dose for the whole lips.

실험적: Group 2 - Nasolabial folds (NLF)
HLR-2, maximum of 3ml per NLF, (1.5ml max at the touch-up treatment, if performed) injected in the mid to deep dermis.

Initial injection of HLR-1 and a touch-up treatment can occur 30 ± 7 days after the initial treatment if the Injector and Subject determine that additional HLR Dermal Filler would improve the aesthetic outcome.

The Maximum allowable dose for the touch up treatments is half of initial dose by side.

실험적: Group 3 - Cheeks
HLR-3, maximum of 4ml per side, (2 ml max at the touch-up treatment, if performed) injected in the deep dermis or subcutaneous to supraperiosteal layers of the cheeks.

Initial injection of HLR-1 and a touch-up treatment can occur 30 ± 7 days after the initial treatment if the Injector and Subject determine that additional HLR Dermal Filler would improve the aesthetic outcome.

The Maximum allowable dose for the touch up treatments is half of initial dose by side.

연구는 무엇을 측정합니까?

주요 결과 측정

결과 측정
측정값 설명
기간
Responder Rate
기간: 3 months for Group 1, 6 months for Groups 2 and 3

Clinical scoring:

The assessment of lip volume, wrinkles severity of nasolabial folds and cheeks volume will be performed by the ILE and validated with BLE (blinded live evaluator) assessment using the respectively structured scale ROSSI, WSRS or MFVDS. At each scoring event, one score for the upper lip will be given for subjects in group 1, two scores for right and left NLF for subjects in group 2 and two scores for right and left cheeks for subjects in group 3.

For each group, in order to demonstrate a product efficacy, the responder rate proportion in clinical scoring should be significantly higher than 60% using a one-tailed binomial test at the Alpha=0.05 significance level.

3 months for Group 1, 6 months for Groups 2 and 3
Safety Evaluation
기간: 12 months after the injection

Prior to statistical analyses, all the AEs will be coded using the Medical Dictionary MedDRA®.

Will be presented by System Organ Class and Preferred Term:

  • All Adverse Events
  • All Serious Adverse Events
  • All Adverse Device Effects

The number and percentage of patients experiencing at least one AE / SAE / ADE occurring over 6 months and 12 months after the injection will be provided as well.

AEs will also be tabulated by:

  • Seriousness criterion
  • Severity
  • Relationship with the product
  • Relationship with CIP procedure
  • Outcome

The individual listing of AE will be provided. The main analysis will be performed globally on the entire safety population over the 3 groups. Analysis per group will also be realized, as well as broken down by sub-group of subjects with and without touch-up.

12 months after the injection

공동 작업자 및 조사자

여기에서 이 연구와 관련된 사람과 조직을 찾을 수 있습니다.

연구 기록 날짜

이 날짜는 ClinicalTrials.gov에 대한 연구 기록 및 요약 결과 제출의 진행 상황을 추적합니다. 연구 기록 및 보고된 결과는 공개 웹사이트에 게시되기 전에 특정 품질 관리 기준을 충족하는지 확인하기 위해 국립 의학 도서관(NLM)에서 검토합니다.

연구 주요 날짜

연구 시작 (실제)

2023년 1월 9일

기본 완료 (추정된)

2027년 1월 1일

연구 완료 (추정된)

2027년 1월 1일

연구 등록 날짜

최초 제출

2026년 8월 9일

QC 기준을 충족하는 최초 제출

2026년 8월 9일

처음 게시됨 (실제)

2026년 8월 13일

연구 기록 업데이트

마지막 업데이트 게시됨 (실제)

2026년 8월 13일

QC 기준을 충족하는 마지막 업데이트 제출

2026년 8월 9일

마지막으로 확인됨

2026년 8월 1일

추가 정보

이 연구와 관련된 용어

기타 연구 ID 번호

  • HL01IL2022

약물 및 장치 정보, 연구 문서

미국 FDA 규제 의약품 연구

아니

미국 FDA 규제 기기 제품 연구

아니

이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .

구독하다